Search results
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study...
KOIN News 6 Portland· 3 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves...
Clearfield Progress· 6 days agoAkeso, Inc. (HKEX: 9926.HK) ("Akeso," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoLive from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC PR Newswire SUZHOU, China, and ROCKVILLE, Md., June 1, 2024 SUZHOU, China ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 3 days agoInnovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting PR Newswire SAN FRANCISCO and SUZHOU, China, June 2, 2024 SAN FRANCISCO and